DSIP (delta sleep-inducing peptide)
DSIP: What The Studies Actually Say
It is sold as the deep-sleep peptide. The human studies are small and mostly from the 1980s, the only insomnia trial with a separate placebo group found weak effects, and nobody knows how it works. Here is what the research actually found.
Updated 22 September 2026
Before you read this
This page explains what published studies found. That is all it is. It is not medical advice, and it is not instructions for using anything. Nothing here is meant to find, treat, cure or stop any illness. The compounds discussed on this site, retatrutide included, are not approved by the FDA for use in people. Research compounds are sold for laboratory use only — not for use in humans or animals. A study tells you what happened to the people in it. It does not tell you what would happen to you. What you do with what you read here is your responsibility, so talk to a doctor first. This page is published by Ascend Vials, which sells research compounds.
Read the full guide
Confirm you have read the notice above and enter an email address. We will send you a link back to this guide, and sometimes an email when we publish a new one. You can unsubscribe any time.
You have probably heard DSIP called the deep-sleep peptide. The name comes from an experiment in rabbits in 1977. The human studies since then are small, old, and they do not agree.
Here is what the research actually found. Every claim has a link. Read them yourself.
The 30-second version
- DSIP is a peptide nine amino acids long. It got its name because it boosted deep-sleep brainwaves in rabbits.
- The human evidence is small and old. Every sleep study had 18 people or fewer, and almost all of the human work is from 1981 to 1998.
- The only insomnia trial with a separate placebo group had 16 patients. Its authors called the effects weak.
- Nobody knows how it works. FDA said so in 2026. And in one study, the body's own levels were lowest at 1 a.m.
- Every controlled human study injected it into a vein. There is no human data for injection under the skin.
- It is not approved in the US, and it is not on the EU's central list of medicines. Russia registers a nasal product that contains it. In July 2026 an FDA advisory panel voted 7 to 6 against adding it to the list US pharmacies can compound from.
- Nothing sold online has been shown to match what the studies used. No study has checked.
What it is
DSIP stands for delta sleep-inducing peptide, a chain of nine amino acids. FDA uses its official drug name, emideltide. FDA briefing, 2026 In Russia it is sold in a nasal product called Deltaran. Vidal
Scientists found it in rabbits in 1977. Dripped into a rabbit's brain, it boosted delta waves, the slow brainwaves of deep sleep. That is where the name comes from. PNAS, 1977
Antibody tests have picked up something like it in human blood and spinal fluid, and in urine and breast milk. Source · Source But a 2006 review said no gene or receptor for it had been found. It called the case that DSIP is a natural sleep signal very poorly documented and weak. J Neurochem, 2006
It does not last. In human blood, half of it is reported gone in 7 to 8 minutes. Anaesthesia editorial, 2001
In the US, clinics, med spas and online stores sell it as injections and nasal sprays. FDA says none of the sites it checked say which form of the molecule they sell. FDA briefing, 2026
The sleep studies are small, old and mixed
We found eight reports of DSIP and sleep in people. Every one injected it into a vein.
| People | Separate placebo group? | What was reported | |
|---|---|---|---|
| Healthy people, 1981 | 6 | No — same people, swapped days | 59% more sleep in the next 130 minutes |
| Insomnia, 1981 | 6 | No — same people, swapped nights | FDA: only "tendencies" |
| Insomnia, 1984 | 7 | No — not blinded | Sleep "normalized" in 6 of 7 |
| Narcolepsy, 1984 | 1 | No | Sleep attacks fell from 6 a week to 3 |
| Insomnia, 1986 | 18 | No — fake drip on the first nights only | 57 to 97 more minutes of sleep |
| Insomnia, 1987 | 14 | No — fake drip only before and after | 72 more minutes of sleep |
| Insomnia, 1987 | 6 | No — same people, swapped nights | Authors: little clinical value |
| Insomnia, 1992 | 16 | Yes | Weak effects |
Sources, in order: 1981 · 1981 · 1984 · 1984 · 1986 · 1987 · 1987 · 1992 · FDA briefing, 2026
Read the whole table. Only one of the eight put a separate group of people on a fake drip.
Here is the 1987 study of 14 people with insomnia, who got DSIP every night for a week.
They also fell asleep faster: 28 minutes instead of 58. But nobody got a fake drip for the week. The patients were compared with outside healthy sleepers, and FDA said it could not tell whether the changes mattered clinically. Eur Neurol, 1987 · FDA briefing, 2026
The first human test, in six healthy people, found 59% more sleep over the next 130 minutes than on a fake drip. Six is a very small test. Int J Clin Pharmacol, 1981
The one trial with a separate placebo group gave 16 people with long-term insomnia DSIP or a sugar-water drip for three nights. The authors called the effects weak and partly down to a chance change in the placebo group. Patients' own rating of their sleep did not change. The authors doubted DSIP would be of major benefit. Neuropsychobiology, 1992 FDA found no significant difference between the groups. FDA briefing, 2026
So the honest line is this: the biggest insomnia results come from studies without a proper placebo comparison. In the three insomnia trials that had one — the same people on swapped nights, or a separate group — the effects were small, weak or not significant.
The body's own DSIP does not act like a sleep signal
If DSIP were the body's sleep switch, you would expect more of it at night.
In 12 volunteers measured around the clock, levels peaked at 3 p.m. and were lowest at 1 a.m. They were lower in deep sleep and dream sleep than when awake, and followed body temperature instead. J Clin Endocrinol Metab, 1994 In 7 men, levels dropped when sleep began. Source
Even those numbers may be off. A pig-brain peptide with a completely different make-up also sets off the antibody tests, so some "DSIP" may be something else. Eur J Biochem, 1993
The rabbit result has not always repeated. A 1980 rat study found no extra sleep. Waking Sleeping, 1980 FDA says nobody has explained why animal results disagree. FDA briefing, 2026
Under anaesthesia it did the opposite. In a trial of 24 women having surgery, 12 got DSIP and 12 got salt water. At the lowest amount tested, DSIP cut delta brainwaves and made the anaesthesia lighter — the reverse of its name. It also raised heart rate. Eur J Anaesthesiol, 2009
Withdrawal and hormones
DSIP was also tried in people coming off alcohol and opioids. None of these studies had a comparison group.
- 1983: of 49 people who could be assessed, doctors said 48 got better. Another 18 were lost or could not be assessed. Neuropsychobiology, 1983
- 1984: in 107 patients, staff judged that 97% of opioid and 87% of alcohol patients improved a lot. There was no blinding and no standard scale. Some "successes" fell back into anxiety and bad insomnia within 3 days of stopping. Eur Neurol, 1984 · FDA briefing, 2026
- 1998: only 2 of 7 opioid patients finished the course, and both needed a sleep medicine by day 3. The authors called it an open question whether DSIP could work. J Clin Psychopharmacol, 1998 · FDA briefing, 2026
Growth hormone. You may read that DSIP raises it. In the one controlled test, in 8 healthy women, it had no effect. Psychoneuroendocrinology, 1993 A small uncontrolled Russian study reported growth hormone going down. Adv Gerontol, 2004
Stress hormones. In 11 healthy men, one shot lowered ACTH, a signal that drives the stress hormone cortisol, for at least 3 hours. Cortisol itself did not change. Psychoneuroendocrinology, 1989 Another team found no effect on either. Psychoneuroendocrinology, 1995
Animals and cells
- Rat heart attacks. Given while the artery was blocked, all 10 rats died within 30 minutes. Given just after blood flow returned, the damaged area was smaller: 28.7% of the area at risk, against 42.1% on salt water. The report gives few details of the first test. Biomedicines, 2021
- Mouse lifespan. The only study used Deltaran, which also contains glycine. Average lifespan did not change. FDA says the glycine muddies the tumor results and the study was not built to judge cancer. Mech Ageing Dev, 2003 · FDA briefing, 2026
- Swallowing it. In a lab model of the human gut lining, none got through intact. Drug Metab Dispos, 1995
What is known about safety
FDA counted 209 people who got DSIP into a vein in published studies, for 1 to 15 days. It found no human safety data for injection under the skin. FDA briefing, 2026
The biggest study gives the clearest picture:
| Of 107 patients (1984) | People |
|---|---|
| No significant side effects | 95 |
| Minor, short-lived: sweating, headache, nausea, dizziness | 9 |
| Serious reactions | 3 |
Two of the serious reactions were drops in blood pressure at the first shot. The third was repeated spells of feeling unwell, with sweating and nausea. Withdrawal causes symptoms like these too. FDA briefing, 2026
- Blood-pressure drugs. A 2001 editorial named captopril, a blood-pressure drug, as a possible interaction, and said people on that type of drug should probably not get DSIP until more is known. Anaesthesia editorial, 2001 FDA flags captopril too. FDA briefing, 2026
- Immune reactions. FDA warns injected peptides can set off the immune system, and that shots under the skin generally carry more of that risk. FDA briefing, 2026
- Missing studies. FDA found none on repeated doses, gene damage, pregnancy, long-term cancer risk or abuse. FDA briefing, 2026
- The Russian label lists allergic reactions and nose irritation. It rules out pregnancy, breastfeeding and under-18s, and warns against it with a very slow heartbeat. Vidal
No reports is not the same as safe. FDA's side-effect database held no DSIP reports up to March 2024. With no approved product, that proves very little. FDA briefing, 2026
Is it approved?
DSIP is not approved in the United States. Russia registers a nasal product that contains it.
- United States: not approved, and not part of any approved drug. FDA briefing, 2026
- Compounding: FDA says it lacks enough information to know whether DSIP would cause harm in people. FDA Its reviewers recommended against allowing it for opioid withdrawal, insomnia or narcolepsy. FDA briefing, 2026
- The July 2026 vote: FDA's advisory committee voted 7 to 6 against adding it. STAT · FDA meeting page The vote is not binding, and we found no FDA proposed rule on it as of 22 September 2026. Federal Register
- Russia: registered as Deltaran, a nasal product that mixes DSIP with glycine, sold without a prescription. Its label lists it for use together with other medicines in stress-related conditions, alcohol withdrawal and alcohol craving. Vidal · RLS FDA's review found DSIP registered in no country it searched, and does not mention this product. FDA briefing, 2026
- Europe: not on the EU's central list of approved medicines. We did not check each country. EMA
- Trials: ClinicalTrials.gov lists no registered DSIP trial. ClinicalTrials.gov
What is still unknown
- How it works, and how the body handles it. FDA said in 2026 that both are unknown.
- Anything about injecting it under the skin, or whether a nasal spray reaches the human brain.
- Whether it helps sleep in a modern trial of decent size. None is registered.
- Long-term safety of repeated use, including immune reactions and abuse.
- What a "dose" even means. Animal tests hinted that more was not better, and in healthy people the effect reportedly depended on how fast it was dripped in.
- Whether the withdrawal results would hold up against a placebo.
Sources: FDA briefing, 2026 · Eur Neurol, 1984
What is in the bottle is not what was studied
One more thing.
Almost every human result on this page came from DSIP injected into a vein by researchers, mostly between 1981 and 1998.
No study has ever shown that a product sold online as "DSIP" is the same thing. Not the same purity. Not the same strength. Not even proof it is the same molecule. The lab certificates FDA was sent with the requests to compound it had no impurity limits and no test for bacterial toxins. And injection under the skin, the route FDA was asked to allow, has never been tested in a published human study. FDA briefing, 2026
So take every number on this page for what it is. It describes what happened in those studies. It describes nothing else.
How to check a number yourself
You are going to see more claims about DSIP. In a reel. In a comment. On somebody's store page.
Here is how to tell a real one from a marketing one. Five questions. About ten seconds each.
1. Is there a link to a study?
A real number comes from a paper you can open. No link means it is a claim, not a result. Search "delta sleep-inducing peptide" on pubmed.gov yourself, and look at the year on each paper.
2. How many people?
Small studies swing. Every sleep study here had 18 people or fewer.
3. Was there a group on a fake drip?
Without one, nobody can tell how much of the result was the peptide. In the only trial with a separate one, part of DSIP's edge came from a chance change in that group.
4. Was it the same thing, given the same way?
Every controlled human study injected DSIP into a vein. Nobody has tested it under the skin in people. The mouse lifespan study used a product with glycine in it. A result for one is not a result for another.
5. Who ran it?
Five of the eight sleep studies above have the same first author, and both from 1981 also list one of the scientists who discovered DSIP. The two placebo-controlled insomnia trials by other authors both found little.
Now run those five on this page
Every number above links to its paper. You were told which studies had a placebo group, which results came from animals, and which came from a product with something else in it. The biggest sleep numbers have "no placebo group" printed right next to them.
That is the whole difference: a number you can check, and a number you are asked to believe.
This page has a date on it, near the top. If a modern, properly controlled trial of DSIP is ever published, this page changes.
Read the studies yourself
- FDA briefing, 2026 — the fullest review of studies, safety and status
- Discovery in rabbits, 1977 · 2006 review
- Sleep: 1981 · 1981 · 1984 · narcolepsy · 1986 · 1987 · 1987 · 1992, the placebo-group trial
- The body's own levels: 1994 · sleep onset · antibody tests · more · the look-alike peptide
- Animals: rats, 1980 · dose effects, 1984 · rat hearts — free to read · mouse lifespan · gut cells
- Surgery trial, 2009 · Anaesthesia editorial, 2001
- Withdrawal: 1983 · 1984 · 1998
- Hormones: 1989 · 1995 · 1993 · 2004
- Russian label: Vidal · RLS
- FDA compounding: safety-risk list · July 2026 meeting · the vote, STAT · Federal Register
- EMA medicines list · ClinicalTrials.gov
Anything above about amounts describes what a study gave to enrolled people or animals. This is not advice, a plan, or instructions. DSIP is not an approved medicine in the United States. Research compounds are not for human or animal use.